EQL Pharma AB (publ) (EQL)

NASDAQ | Biotech | Pharmaceuticals and niche generics
Intro rate Introductory pricing for early customers through June 30 — the same full analysis at a lower rate while we refine delivery.
Free
No email, no account, no signup.
Pulling latest news for EQL Pharma AB (publ)…
Bull
Bear
Intro rate Introductory pricing for early customers through June 30 — the same full analysis at a lower rate while we refine delivery.

Professional stock analysis at introductory pricing. 7-day money-back guarantee — no lock-in.

Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99 $1.25.
Get the deep 4-model report – $4.99 $1.25
Order analysis – $4.99 $1.25

Professional stock analysis at introductory pricing. 7-day money-back guarantee — no lock-in.

Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Exchange
NASDAQ
Type
Biotech
Sector
Pharmaceuticals and niche generics
Market Cap
$76M
We're already tracking EQL Pharma AB (publ) — here are the latest events we've registered

Recent News

  • On May 8, 2026, EQL Pharma released its year-end report for 2025/26, reporting record quarterly sales of SEK 120.2 million. However, earnings were impacted by one-off items and higher logistics costs driven by geopolitical tensions. The company also announced the recruitment of a new Chief Supply Chain Officer to strengthen its operations.
Want to know how this news affects EQL Pharma AB (publ)? Order the analysis.
Order analysis – $4.99 $1.25

What you get

A complete express analysis — not just a signal. Delivered as a webpage in your account.

  • Signal: BUY / HOLD / SELL — with clear reasoning
  • Sentiment score 1–10 based on news, reports, and market data
  • Risk score 1–10 (dilution, jurisdiction, execution)
  • Bull case: 3–5 specific points with evidence (e.g. "Oversold after panic-reaction to security news, opening a technical bounce setup")
  • Bear case: 3–5 specific risks (e.g. "Extreme uncertainty around the security situation in Sinaloa after tragic events")
  • Upcoming catalysts with dates
  • Sources: news, filings, market data, and investor forums
  • Assessment of dilution risk
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of EQL Pharma AB (publ) will be delivered in the same format.
Order analysis – $4.99 $1.25
Not satisfied? Get your money back within 7 days — no questions asked.
EQL Pharma AB (publ) (EQL)
Fresh analysis on demand
Buy express analysis – $4.99 $1.25
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.